TLX1/N fundamentals
An in-depth look to TELIX PHARMACEUTIC operating, investing, and financing activities
TLX1/N free cash flow for H1 24 is 369.42 M MXN. For 2023, TLX1/N free cash flow was 164.25 M MXN and operating cash flow was 276.17 M MXN.
Q1 '24
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: MXN
Q1 '24
TTM